WeTrials
Completed

Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients With Advanced Solid Tumors

What is this study?

This study is testing an experimental medication called PM14 in people with advanced solid tumors that have spread and no longer respond to standard treatments. Researchers want to find the safest and most effective dose of this new drug to help future patients.

Who can participate?

You may be able to join if you are 18 or older, can still do your daily activities easily, and have an advanced solid tumor without standard cure options. However, you cannot join if you have uncontrolled high blood pressure, certain heart conditions, or significant heart valve disease.

What will happen?

Participants will receive the study medication, PM14, directly into their veins while doctors closely monitor their health, side effects, and how the drug moves through their body. The study starts with lower doses to ensure safety before gradually increasing them.

Where and when?

This completed study took place at medical centers in Boston and Houston in the United States, as well as in Villejuif, France. It has now finished its initial testing phase.

Key Points
  • 1Tests a new experimental drug called PM14 for advanced solid tumors
  • 2Helps researchers find the safest dose for future cancer treatments
  • 3Requires participants to be 18 or older with good daily functioning

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Solid Tumor

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.